AGIO Rasio cepet Agios Pharmaceuticals

Agios Pharmaceuticals develops therapies for rare pathologies through partnerships with scientists and enzyme licensing. The immediate liquidity position reflects the dynamics of cash and accounts receivable, where 9.93 represents the current metric. The business is currently reorienting its portfolio toward genetic blood diseases while maintaining a stable cash flow. The company's environmental policy is based on the safe disposal of reagents and water conservation.

Stress-testing positions requires analyzing a business's ability to immediately settle debts without accounting for slow-moving inventories. For Agios Pharmaceuticals (AGIO), which invests in the complex biochemistry of cellular metabolism, the quick ratio demonstrates the real liquidity buffer by excluding inventory and leaving only cash and accounts receivable to assess the financial stability of its innovations.